From bench scientist to CSO - a Journey of entrepreneurial science
27 November 2025 - Ghent ICC
Peter Ulrichts, CSO at argenx, explores his fascinating journey from scientist to Chief Scientific Officer. He will cover his personal career path, what attracted him to argenx, and will discuss the differences between academic and industry careers. The concept of argenx’s entrepreneurial science will be highlighted, focusing on the company's culture of innovation, co-creation, and empowerment. Career opportunities and the broad range of scientific careers available at argenx will be discussed, emphasizing the importance of thinking big, moving fast, and collaborating to deliver significant impact in the field of immunology. The talk will conclude with insights into the company's vision for the future and its commitment to redefining what is possible for science, patients, and society.About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Peter Ulrichts | Chief Scientific Officer | argenx
Peter Ulrichts is the Chief Scientific Officer at argenx and joined the company in 2010. In this role, he oversees the development of all clinical and pre-clinical compounds within argenx’s pipeline. Peter joined the company as a research scientist where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. While at argenx, he headed the development of argenx’ FcRn antagonist efgartigimod until the first-in-human study, after which he transitioned to become the lead scientist of the efgartigimod program. Peter holds a B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and Ph.D. in Immunology, both from the University of Ghent (Belgium).
Peter Ulrichts | Chief Scientific Officer | argenx
Peter Ulrichts is the Chief Scientific Officer at argenx and joined the company in 2010. In this role, he oversees the development of all clinical and pre-clinical compounds within argenx’s pipeline. Peter joined the company as a research scientist where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. While at argenx, he headed the development of argenx’ FcRn antagonist efgartigimod until the first-in-human study, after which he transitioned to become the lead scientist of the efgartigimod program. Peter holds a B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and Ph.D. in Immunology, both from the University of Ghent (Belgium).
| For job seekers | For employers | Join BCF Career Event |
| | Register BCF BE | |
| Powered by: Hyphen Projects Privacy Policy Terms & Conditions Chamber of Commerce: 32110979 |
© Copyright 2025 by Hyphen Projects